Achalasia is a rare esophageal motility disorder characterized by the inability of the lower esophageal sphincter to relax and the absence of normal esophageal peristalsis. This condition leads to difficulties in swallowing (dysphagia), regurgitation of food, and chest pain. Clinical observations suggest an association between achalasia and esophageal tumors, as achalasia can increase the risk of developing esophageal cancer. We explore the pathophysiology of achalasia, its clinical manifestations, and the associated risk of esophageal malignancies, supported by recent research and clinical evidence, including specific case studies.

Ayya Azzahra of CervivAI from Indonesia and Neda Razavi of iSono Health from the United Sstates were announced as the two winners of Qatar Foundation’s World Innovation Summit for Health (WISH) 2024 Innovation Competitions during the closing ceremony of its 2024 summit.

The p95HER2 protein is found expressed in one third of HER2+ tumors, which represent 4% of all tumors. Led by VHIO investigators, CAR T cells targeting p95HER2 have been engineered to secrete the TECH2Me bispecific antibody. Both therapies specifically and independently recognize tumor cells. In addition, the TECH2Me bispecific antibody activates immune cells within the tumor microenvironment.

 

BUFFALO, NY - November 18, 2024 – A new editorial was published in Oncotarget's Volume 15 on November 12, 2024, entitled, “Mitigating bias in radiology: The promise of topological data analysis and simplicial complexes.”

Bisphenols used in manufacturing products as ‘harmless’ alternatives to BPA pose a health risk, according to a UMH study. Many bisphenols present in everyday items interfere with the body’s hormones. These chemicals are associated with an increased risk of obesity, diabetes, and cancer.

A team of researchers from NIH’s National Library of Medicine and National Cancer Institute developed an AI algorithm that could successfully identify relevant clinical trials for which a person is eligible and provide a summary that clearly explains how that person meets the criteria for study enrollment. The tool can help make it easier for both clinicians and patients to find and connect with the right clinical trial opportunities.

Funded by the BBVA Foundation, the event is taking place from 18 until 20 November at the Casa de Convalescència.

The conference aims to drive new therapeutic strategies to improve cancer treatment.